Transcatheter Pulmonary Valve (TPV) therapy has emerged as the most widely adopted treatment for people with congenital heart disease who suffer the degeneration of the previous right ventricular outflow tract (RVOT) repair. TPV therapy is significant for the treatment of post-operative RVOT obstruction and other heart conditions that need surgical RVOT reconstruction. Various minimally invasive catheter-based interventions have been developed worldwide to treat pulmonary valve dysfunction and avoid repetitive median sternotomy procedures. There are two TPV systems, namely, the Melody® TPV (Medtronic Inc.) and the Sapien® transcatheter heart valve (Edwards Lifesciences LLC), which are widely in investigational or commercial use. The Melody® valve is specially designed to replace the transcatheter pulmonary valve. In contrast, the Sapien® valve was initially intended for transcatheter aortic valve replacement, and it is now used for pulmonary circulation.
The global Transcatheter Pulmonary Valve (TPV) therapy market is poised to gain major traction over the upcoming years. The market growth can be attributed to a slew of factors, such as the rising incidence of cardiovascular diseases and diabetes, the growing prevalence of congenital heart disease and congestive heart disease (CHD), and the surging awareness about transcatheter pulmonary valve therapy. Transcatheter pulmonary valves extend the functional life of an RV-PA conduit, restore pulmonary valve competence, and relieve conduit stenosis. Thus, the demand for these valves has profoundly risen globally, triggering the global market growth during the projected timeline. However, market growth is hampered due to the slow-paced adoption of TPV therapy in developing and low-income countries. Moreover, the emergence of newer technologies and the burgeoning demand for minimally invasive cardiac procedures are certain factors causing hindrances to market growth.
Among the key market regions, North America and Europe Transcatheter Pulmonary Valve (TPV) therapy markets have been leading globally and are expected to maintain their dominance over the forecast years. The availability of skilled healthcare professionals, increasing incidence of cardiovascular diseases, and advanced healthcare infrastructure across these regions are the significant growth propellers for these markets. The Asia Pacific market is expected to witness moderate growth in the coming years. Rapidly advancing healthcare facilities, surging healthcare awareness, and a favorable regulatory environment are likely to contribute to the market growth in this region. Several APAC countries, including China, Japan, and India, are the key growth engines for the Asia Pacific market.
Medtronic plc, Venus Medtech, Cryolife Inc., and Edwards Lifesciences Corporation are some of the leading competitors in this market. Medtronic, the globally leading medical device company, had recently unveiled positive outcomes from two of its clinical trials involving the Melody TPV Therapy and the Harmony TPV Therapy. The Melody TPV trial showed positive safety and hemodynamic outcomes and the investigational Harmony TPV therapy clinical trial turned out to be safe and effective for hemodynamic function.
Read Full Press Release @ https://www.reportsanddata.com/press-release/global-transcatheter-pulmonary-valves-tpv-therapy-market
No comments:
Post a Comment